Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents. Combination of PARPis with agents that inhibit HR may repres...
Main Authors: | , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058036/ |